187 related articles for article (PubMed ID: 33097493)
1. sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
Fane ME; Ecker BL; Kaur A; Marino GE; Alicea GM; Douglass SM; Chhabra Y; Webster MR; Marshall A; Colling R; Espinosa O; Coupe N; Maroo N; Campo L; Middleton MR; Corrie P; Xu X; Karakousis GC; Weeraratna AT
Clin Cancer Res; 2020 Nov; 26(21):5709-5719. PubMed ID: 33097493
[TBL] [Abstract][Full Text] [Related]
2. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.
Roda JM; Sumner LA; Evans R; Phillips GS; Marsh CB; Eubank TD
J Immunol; 2011 Aug; 187(4):1970-6. PubMed ID: 21765015
[TBL] [Abstract][Full Text] [Related]
4. The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus.
Siamakpour-Reihani S; Caster J; Bandhu Nepal D; Courtwright A; Hilliard E; Usary J; Ketelsen D; Darr D; Shen XJ; Patterson C; Klauber-Demore N
PLoS One; 2011; 6(6):e20412. PubMed ID: 21673995
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
6. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
[TBL] [Abstract][Full Text] [Related]
7. Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.
Schuster C; Akslen LA; Straume O
PLoS One; 2016; 11(5):e0155242. PubMed ID: 27166673
[TBL] [Abstract][Full Text] [Related]
8. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
Bannoud N; Stupirski JC; Cagnoni AJ; Hockl PF; Pérez Sáez JM; García PA; Mahmoud YD; Gambarte Tudela J; Scheidegger MA; Marshall A; Corrie PG; Middleton MR; Mariño KV; Girotti MR; Croci DO; Rabinovich GA
Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2214350120. PubMed ID: 36634146
[TBL] [Abstract][Full Text] [Related]
9. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
10. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.
Kaur A; Webster MR; Marchbank K; Behera R; Ndoye A; Kugel CH; Dang VM; Appleton J; O'Connell MP; Cheng P; Valiga AA; Morissette R; McDonnell NB; Ferrucci L; Kossenkov AV; Meeth K; Tang HY; Yin X; Wood WH; Lehrmann E; Becker KG; Flaherty KT; Frederick DT; Wargo JA; Cooper ZA; Tetzlaff MT; Hudgens C; Aird KM; Zhang R; Xu X; Liu Q; Bartlett E; Karakousis G; Eroglu Z; Lo RS; Chan M; Menzies AM; Long GV; Johnson DB; Sosman J; Schilling B; Schadendorf D; Speicher DW; Bosenberg M; Ribas A; Weeraratna AT
Nature; 2016 Apr; 532(7598):250-4. PubMed ID: 27042933
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab treatment of meningeal melanoma metastases.
Simonsen TG; Gaustad JV; Rofstad EK
J Transl Med; 2020 Jan; 18(1):13. PubMed ID: 31915016
[TBL] [Abstract][Full Text] [Related]
12. Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.
Sanches Jde S; de Aguiar RB; Parise CB; Suzuki JM; Chammas R; de Moraes JZ
Cancer Sci; 2016 Apr; 107(4):551-5. PubMed ID: 27079440
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
[TBL] [Abstract][Full Text] [Related]
14. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.
Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y
Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802
[TBL] [Abstract][Full Text] [Related]
16. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.
Yang L; You S; Kumar V; Zhang C; Cao Y
J Exp Clin Cancer Res; 2012 May; 31(1):40. PubMed ID: 22549243
[TBL] [Abstract][Full Text] [Related]
17. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
18. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
19. Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH.
Tsiros D; Sheehy CE; Pecchia S; Nugent MA
J Biol Chem; 2019 Nov; 294(46):17603-17611. PubMed ID: 31601651
[TBL] [Abstract][Full Text] [Related]
20. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
